View Drug - InterSol
Jump to: Basic Info Purpose Indications Warnings Reactions

InterSol

Generic: PLATELET ADDITIVE 3

100%
Basic Information
Manufacturer
Fenwal, Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
INTRAVENOUS
FDA Set ID
a00c4a93-cde2-4753-81f7-0d6fee9fb690
Indications & Usage
Rx only Store at Controlled Room Temperature.

Protect from freezing.

Avoid excessive heat.

Definition of "Controlled Room Temperature": "A temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15°C and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses.

Provided the mean kinetic temperature remains in the allowed range, transient spikes up to 40°C are permitted as long as they do not exceed 24 hours ...

The mean kinetic temperature is a calculated value that may be used as an isothermal storage temperature that simulates the non isothermal effects of storage temperature variations." Reference: United States Pharmacopeia, General Notices.

United States Pharmacopeial Convention, Inc.

12601 Twinbrook Parkway, Rockville, MD.

Dispose of waste in appropriate biohazard container or according to local regulatory requirements.

Indications and Usage: InterSol solution is an isotonic solution designed to replace a proportion of the plasma used in the storage of leukoreduced apheresis platelets under standard blood banking conditions.

There is no direct therapeutic effect to be expected from the formulation.

The solution should never be infused directly into a patient.

InterSol platelets are leukocyte-reduced apheresis platelet concentrates that are stored in a mix of 65% InterSol and 35% plasma, nominal.

InterSol platelets prepared within the ranges described in the apheresis system Operator's Manuals may be stored for up to 5 days at 20-24°C, with continuous agitation.
Adverse Reactions
Adverse Reactions: InterSol solution is added to leukoreduced platelet concentrates after the apheresis procedure is complete.

It is not for direct intravenous infusion.

InterSol solution is not expected to cause adverse events other than those normally associated with platelet transfusion.